TAGCyx Biotechnologies Inc.
PrivateLast Round
Grant
Apr 16, 2026
Total Funding Raised
$13.31M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
TAGCyx Biotechnologies Inc. operates in Healthcare & Life Sciences and is based in Tokyo. Its latest recorded funding round was a Grant round in April 2026.
TAGCyx Biotechnologies Inc. is a biotechnology company that develops oligonucleotide aptamer-based pharmaceuticals and medical devices using its proprietary Xenoligo® drug discovery platform.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Medical Devices
Business Model
B2B
Customer Profile
Services & Consulting, Revenue Share
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
TAGCyx Biotechnologies Inc. Comparables
Compare TAGCyx Biotechnologies Inc. with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Raptamer Therapeutics | 83% | |
| Guardian Therapeutics | 81% | |
| Aptagen, LLC | 79% |
For institutional investors. Book with your work email.
TAGCyx Biotechnologies Inc. Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Apr 16, 2026 | ||||
| Series C Extension | Jul 7, 2021 | ||||
| Series C | May 18, 2020 | ||||
| Series B | Apr 27, 2018 | ||||
| Series A | Aug 31, 2016 |
For institutional investors. Book with your work email.
TAGCyx Biotechnologies Inc. Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Japan Agency for Medical Research and Development | Grant |
| Mizuho Capital | Series B |
| UTEC (The University of Tokyo Edge Capital Partners) | Series B, Series A |
| Nissay Capital | Series A |
| 株式会社ヘルスケア・イノベーション | Series C Extension |
| SBI Holdings | Series C Extension |
| SMBC Venture Capital | Series B, Series A |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Apr 16, 2026
Received grant from Japan Agency for Medical Research and Development.
- May 18, 2020
$1.87M round led by UTokyo Innovation Platform.
For institutional investors. Book with your work email.
TAGCyx Biotechnologies Inc. Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about TAGCyx Biotechnologies Inc.'s valuation, stock price, and market status.
Is TAGCyx Biotechnologies Inc. a public or private company?
TAGCyx Biotechnologies Inc. is a private company.
What is the current stock price of TAGCyx Biotechnologies Inc.?
TAGCyx Biotechnologies Inc. is a private company, so its shares have no public market price. Caplight tracks TAGCyx Biotechnologies Inc.'s secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is TAGCyx Biotechnologies Inc. worth (valuation)?
Valuation information for TAGCyx Biotechnologies Inc. is not publicly available.
Can I buy TAGCyx Biotechnologies Inc. stock?
TAGCyx Biotechnologies Inc. shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was TAGCyx Biotechnologies Inc.'s last funding round?
TAGCyx Biotechnologies Inc.'s most recent funding round was Grant on April 16, 2026.
Who are the main investors in TAGCyx Biotechnologies Inc.?
Key investors in TAGCyx Biotechnologies Inc. include UTEC (The University of Tokyo Edge Capital Partners).
Will TAGCyx Biotechnologies Inc. IPO soon?
No public IPO plans have been announced for TAGCyx Biotechnologies Inc..
How can I track TAGCyx Biotechnologies Inc. secondary market activity?
Caplight tracks bids, offers, and trades in TAGCyx Biotechnologies Inc.'s shares on secondary markets.